Bayer Expert Monday Series: Strategic Interests in External Innovation: Vividion

Join Us for the Bayer Expert Monday Series!

Attention Innovators and Early Stage Entrepreneurs!

Bayer is excited to host the 2025 Bayer Expert Monday series, designed specifically for innovative minds in the life sciences. This virtual series provides you with exclusive access to Bayer experts who will share their invaluable insights, experiences, and guidance to help you navigate the complexities of pharmaceutical development.

If you are an early stage entrepreneur, work with startups, or interested in advancing your knowledge in pharmaceutical development, particularly in oncology, cell and gene therapy, cardiovascular/renal, and immunology, secure your spot and register today! Don’t miss this opportunity to learn from the best and elevate your entrepreneurial journey! We look forward to seeing you at our first session and supporting your mission to innovate in the pharmaceutical industry!

What to Expect:

Expert Insights: Each session will feature a leading expert from Bayer, covering a range of topics including drug discovery, regulatory pathways, clinical trials, and commercialization strategies, with a focus on our strategic areas of interest: oncology, cell and gene therapy, cardiovascular/renal, and immunology.
Interactive Q&A: Engage directly with our experts during live Q&A sessions, allowing you to ask your most pressing questions and gain tailored advice for your entrepreneurial journey.
Networking Opportunities: Connect with fellow early stage entrepreneurs and build valuable relationships within the pharmaceutical community.

Matt Patricelli, PhD, is the Chief Scientific Officer at Vividion Therapeutics, where he leads all discovery and preclinical research efforts, overseeing the Chemistry, Biology, and Preclinical Development departments. A founding scientist and first employee of Vividion, he played a key role in establishing the company’s screening platform and early discovery efforts, contributing to its $2 billion acquisition by Bayer in 2021. With over 20 years of experience in enzymology, chemical biology, chemical proteomics, and drug discovery, he has been instrumental in advancing small-molecule inhibitor programs.

Prior to Vividion, Dr. Patricelli was Senior Director of Biology at Wellspring Biosciences, where he led drug discovery programs. Earlier, as the first scientist at ActivX Biosciences, he helped develop the chemical proteomics methodologies that formed the foundation of its platform. He earned his B.Sc. in Biochemistry from McGill University and his PhD from The Scripps Research Institute as the first graduate student of Dr. Benjamin Cravatt. He is an author or co-author of more than 40 scientific publications and holds six issued patents.

What you need to know:

Each one-hour Bayer's Expert Monday includes a live Q&A with respective Bayer Experts.
These sessions are not intended for service providers, consultants, IT providers, etc. They are designed for drug developers and healthcare researchers seeking collaboration with big pharma and out-licensing opportunities later in their journey.
Session recordings are NOT distributed afterward. Live attendance is necessary to get the most out of the expert sessions and network with the Bayer Pharma team.
Each session has a maximum capacity of 500 participants.